Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: A retrospective actuarial claims data analysis

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1425-1429

  Fitch, Kathryn ^a   Iwasaki, Kosuke ^a   Pyenson, Bruce ^a   Plauschinat, Craig ^b   Zhang, Jie ^b  

^a MILLIMAN INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; GOLD treatment guidelines; Inhaled corticosteroids; Long acting bronchodilators

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DATA ANALYSIS; DISEASE SEVERITY; HUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY;

ACTUARIAL ANALYSIS; ADULT; AGED; BRONCHODILATOR AGENTS; GUIDELINE ADHERENCE; HUMANS; INSURANCE CLAIM REVIEW; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79958816304     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.583230     Document Type: Article

References (13)

1. NHLBI Morbidity and Mortality Chart Book, 2004, National Heart, Lung and Blood Institute: Bethesda, MD.
2. Pauwels RA, Buist AS, Calverley PMA, et al., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-76. (Pubitemid 32378468)
3. Rand CS. Patient adherence with COPD therapy. Eur Respir Rev 2005;14: 97-101. (Pubitemid 43028766)
4. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008;3:371-84.
5. Mularski RA, Asch SM, Shrank WH, et al. The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes. Chest 2006;130:1844-50. (Pubitemid 46033444)
6. Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest 2000;117:33S-7S. (Pubitemid 30111562)
7. Feifer RA, Aubert R, Verbrugge RR, et al. Disease management opportunities for chronic obstructive pulmonary disease: gaps between guidelines and current practice. Dis Manag 2002;5:143-56.
8. Diette GB, Orr P, Mccormack MC, et al. Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines? Popul Health Manag 2010;13:21-6.
9. Singh S, Amin AV, and Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a metaanalysis. Arch Intern Med 2009;169:219-29.
10. Wu EQ, Birnbaum HG, Cifaldi M, et al. Development of a COPD severity score. Curr Med Res Opin 2006;22:1679-87. (Pubitemid 44449224)
11. Hoogendoorn M, Rutten-Van Molken MP. Hoogenveen RT, et al., A dynamic population model of disease progression in COPD. Eur Respir J 2005;26: 223-33. (Pubitemid 41079065)
12. Miravitlles M, De La Roza C, Naberan K, et al. Use of spirometry and patterns of prescribing in COPD in primary care. Respir Med 2007;101: 1753-60. (Pubitemid 46947875)
13. Steuten LM, Creutzberg EC, Vrijhoef HJ, et al. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 2006;15:84-91